IN2014DN09261A - - Google Patents
Info
- Publication number
- IN2014DN09261A IN2014DN09261A IN9261DEN2014A IN2014DN09261A IN 2014DN09261 A IN2014DN09261 A IN 2014DN09261A IN 9261DEN2014 A IN9261DEN2014 A IN 9261DEN2014A IN 2014DN09261 A IN2014DN09261 A IN 2014DN09261A
- Authority
- IN
- India
- Prior art keywords
- genomic locus
- target genomic
- compositions
- methods
- homologous recombination
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261638267P | 2012-04-25 | 2012-04-25 | |
| PCT/US2013/038165 WO2013163394A1 (fr) | 2012-04-25 | 2013-04-25 | Ciblage médié par nucléase avec de grands vecteurs de ciblage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09261A true IN2014DN09261A (fr) | 2015-07-10 |
Family
ID=48289700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9261DEN2014 IN2014DN09261A (fr) | 2012-04-25 | 2013-04-25 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9834786B2 (fr) |
| EP (1) | EP2847335B1 (fr) |
| JP (1) | JP6275120B2 (fr) |
| KR (1) | KR101904508B1 (fr) |
| CN (2) | CN109536526B (fr) |
| AU (1) | AU2013251558B2 (fr) |
| BR (1) | BR112014026294B1 (fr) |
| CA (1) | CA2869016C (fr) |
| CY (1) | CY1120572T1 (fr) |
| DK (1) | DK2847335T3 (fr) |
| ES (1) | ES2683071T3 (fr) |
| HK (1) | HK1207396A1 (fr) |
| IL (1) | IL234905B (fr) |
| IN (1) | IN2014DN09261A (fr) |
| MX (1) | MX362523B (fr) |
| PL (1) | PL2847335T3 (fr) |
| PT (1) | PT2847335T (fr) |
| RU (1) | RU2645475C2 (fr) |
| SG (2) | SG11201406547YA (fr) |
| WO (1) | WO2013163394A1 (fr) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014DN09261A (fr) | 2012-04-25 | 2015-07-10 | Regeneron Pharma | |
| MA37663B1 (fr) | 2012-05-25 | 2019-12-31 | Univ California | Procédés et compositions permettant la modification de l'adn cible dirigée par l'arn et la modulation de la transcription dirigée par l'arn |
| EP3617309A3 (fr) | 2012-12-06 | 2020-05-06 | Sigma Aldrich Co. LLC | Modification et régulation de génome à base de crispr |
| RU2690352C2 (ru) | 2013-02-20 | 2019-05-31 | Регенерон Фармасютикалс, Инк. | Генетическая модификация крыс |
| SI2986729T1 (sl) * | 2013-04-16 | 2019-02-28 | Regeneron Pharmaceuticals, Inc. | Ciljana sprememba genoma podgane |
| ES2844174T3 (es) * | 2013-09-18 | 2021-07-21 | Kymab Ltd | Métodos, células y organismos |
| KR101566498B1 (ko) * | 2013-11-13 | 2015-11-06 | 건국대학교 산학협력단 | 인터루킨 2 수용체 감마 유전자 적중벡터, 그 벡터가 도입된 면역세포 결핍 형질전환 미니 복제돼지 생산과 그 제조방법 및 활용 |
| US10787684B2 (en) * | 2013-11-19 | 2020-09-29 | President And Fellows Of Harvard College | Large gene excision and insertion |
| MX2016007654A (es) | 2013-12-11 | 2017-08-15 | Regeneron Pharma | Metodos y composiciones para la modificacion dirigida de un genoma. |
| CN106795521B (zh) * | 2014-06-06 | 2021-06-04 | 瑞泽恩制药公司 | 用于修饰所靶向基因座的方法和组合物 |
| AU2015279642B2 (en) * | 2014-06-26 | 2021-03-25 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modifications and methods of use |
| WO2016061374A1 (fr) | 2014-10-15 | 2016-04-21 | Regeneron Pharmaceuticals, Inc. | Méthodes et compositions de production ou de conservation de cellules pluripotentes |
| ES2731437T3 (es) | 2014-11-21 | 2019-11-15 | Regeneron Pharma | Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías |
| EP3232774B1 (fr) * | 2014-12-19 | 2019-10-09 | Regeneron Pharmaceuticals, Inc. | Procédés et compositions pour modification génétique ciblée par ciblage multiple en une seule étape |
| WO2016149398A1 (fr) | 2015-03-16 | 2016-09-22 | Regeneron Pharmaceuticals, Inc. | Animal non humain présentant une baisse de la fonction des neurones moteurs supérieurs et inférieurs et de la perception sensorielle |
| ES2784360T3 (es) * | 2015-05-29 | 2020-09-24 | Regeneron Pharma | Animales no humanos que tienen una interrupción en un locus C9ORF72 |
| AU2017336100B2 (en) | 2016-09-30 | 2023-11-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a hexanucleotide repeat expansion in a C9ORF72 locus |
| AU2018295358A1 (en) | 2017-06-27 | 2020-01-16 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ASGR1 locus |
| BR112020001364A2 (pt) | 2017-07-31 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | métodos para testar e modificar a capacidade de uma crispr/cas nuclease. |
| RU2019143568A (ru) | 2017-07-31 | 2021-09-02 | Регенерон Фармасьютикалс, Инк. | Способы и композиции для оценки crispr/cas-индуцированной рекомбинации с экзогенной донорной нуклеиновой кислотой in vivo |
| BR112020001996A2 (pt) | 2017-07-31 | 2020-08-18 | Regeneron Pharmaceuticals, Inc. | animal não humano, e, métodos para testar e para otimizar a capacidade de uma crispr/cas nuclease de excisar um ácido nucleico genômico in vivo, para testar a recombinação induzida por crispr/cas de um ácido nucleico genômico com um ácido nucleico de doador exógeno in vivo e para otimizar a capacidade de crispr/cas de induzir a recombinação de um ácido nucleico genômico com um ácido nucleico de doador exógeno in vivo. |
| NZ761329A (en) | 2017-09-29 | 2023-04-28 | Regeneron Pharma | Non-human animals comprising a humanized ttr locus and methods of use |
| CA3076371C (fr) | 2017-11-10 | 2022-11-22 | Regeneron Pharmaceuticals, Inc. | Animaux non humains comprenant une mutation de slc30a8 et procedes d'utilisation |
| IL274740B2 (en) | 2017-11-30 | 2024-06-01 | Regeneron Pharma | Non-human animals containing a human TRKB locus |
| KR20240038811A (ko) | 2018-03-19 | 2024-03-25 | 리제너론 파마슈티칼스 인코포레이티드 | CRISPR/Cas 시스템을 사용한 동물에서의 전사 조절 |
| US20220053741A1 (en) | 2018-09-13 | 2022-02-24 | Regeneron Pharmaceuticals, Inc. | Complement Factor H Gene Knockout Rat as a Model of C3 Glomerulopathy |
| IL301193A (en) | 2018-12-20 | 2023-05-01 | Regeneron Pharma | Nuclease-mediated repeat expansion |
| ES2966625T3 (es) | 2019-04-04 | 2024-04-23 | Regeneron Pharma | Roedores que comprenden un locus del factor de coagulación 12 humanizado |
| AU2020286382A1 (en) | 2019-06-04 | 2021-11-04 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized TTR locus with a beta-slip mutation and methods of use |
| EP3796776A1 (fr) | 2019-06-07 | 2021-03-31 | Regeneron Pharmaceuticals, Inc. | Animaux non humains comprenant un locus d'albumine humanisé |
| RU2722933C1 (ru) * | 2019-06-11 | 2020-06-05 | Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий | Средство разрезания днк на основе cas9 белка из бактерии demequina sediminicola |
| WO2021108363A1 (fr) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Régulation à la hausse médiée par crispr/cas d'un allèle ttr humanisé |
| EP4096396A1 (fr) | 2020-01-28 | 2022-12-07 | Regeneron Pharmaceuticals, Inc. | Animaux non humains comprenant un locus pnpla3 humanisé et procédés d'utilisation |
| EP4099821A1 (fr) | 2020-02-07 | 2022-12-14 | Regeneron Pharmaceuticals, Inc. | <smallcaps/>? ? ?klkb1? ? ? ? ?animaux non humains comprenant un locushumanisé et procédés d'utilisation |
| US20230102342A1 (en) | 2020-03-23 | 2023-03-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use |
| WO2021263146A2 (fr) | 2020-06-26 | 2021-12-30 | Regeneron Pharmaceuticals, Inc. | Animaux non humains comprenant un locus d'ace2 humanisé |
| JP2024509194A (ja) | 2021-03-05 | 2024-02-29 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インビボｄｎａアセンブリー及び解析 |
| AU2022381205A1 (en) | 2021-11-04 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a modified cacng1 locus |
| AU2022408167A1 (en) | 2021-12-08 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Mutant myocilin disease model and uses thereof |
| WO2023122506A1 (fr) | 2021-12-20 | 2023-06-29 | Regeneron Pharmaceuticals, Inc. | Animaux non humains comprenant des loci ace2 et tmprss humanisés |
| WO2023150798A1 (fr) | 2022-02-07 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Compositions et procédés permettant de définir des délais de traitement optimaux dans le cadre d'une maladie lysosomale |
| WO2023154861A1 (fr) | 2022-02-11 | 2023-08-17 | Regeneron Pharmaceuticals, Inc. | Compositions et procédés de criblage d'agents de ciblage de tau 4r |
| WO2024026488A2 (fr) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Animaux non humains comprenant un locus de récepteur de transférrine modifié |
| WO2024031053A1 (fr) | 2022-08-05 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Variants de tdp-43 résistants à l'agrégation |
| US20240130341A1 (en) | 2022-09-29 | 2024-04-25 | Regeneron Pharmaceuticals, Inc. | Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830729A (en) | 1996-04-18 | 1998-11-03 | Institut Pasteur | I Sce I-induced gene replacement and gene conversion in embryonic stem cells |
| US5830698A (en) * | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
| ATE296356T1 (de) | 1997-03-14 | 2005-06-15 | Biogen Idec Inc | Methode zur spezifischen integration von genen in säugetierzellen durch homologe rekombination, und vektoren zu deren durchführung |
| EP1141360A4 (fr) | 1998-12-31 | 2002-11-06 | David Gladstone Inst | Rongeurs transgeniques et lignees cellulaires de rongeur exprimant des co-recepteurs du vih |
| US6503717B2 (en) * | 1999-12-06 | 2003-01-07 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
| CA2361191A1 (fr) | 1999-02-03 | 2000-08-10 | The Children's Medical Center Corporation | Reparation genique a induction de clivage d'adn bicatenaire en un site cible chromosomique |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| BR0307383A (pt) | 2002-01-23 | 2005-04-26 | Univ Utah Res Found | Mutagênese cromossomica alvo utilizando nucleases de ramificações de zinco |
| WO2003080809A2 (fr) * | 2002-03-21 | 2003-10-02 | Sangamo Biosciences, Inc. | Procedes et compositions permettant d'utiliser des endonucleases a doigts de zinc pour ameliorer la recombinaison homologue |
| JP2006502748A (ja) | 2002-09-05 | 2006-01-26 | カリフォルニア インスティテュート オブ テクノロジー | 遺伝子ターゲッティングを誘発するキメラヌクレアーゼの使用方法 |
| US20030175968A1 (en) | 2002-10-30 | 2003-09-18 | Golic Kent G. | Gene targeting method |
| KR20060002745A (ko) * | 2003-01-13 | 2006-01-09 | 마헨드라 에스 라오 | 치료적 생성물의 전달을 위한 증식성 줄기세포 및전구세포에서의 후보 분자의 지속적 발현 |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| EP1651660B1 (fr) * | 2003-08-08 | 2018-01-24 | Sangamo Therapeutics, Inc. | Methodes et compositions permettant un clivage et une recombinaison cibles |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| EP2292274A1 (fr) | 2004-09-16 | 2011-03-09 | Sangamo BioSciences, Inc. | Compositions et procédés pour la production de protéines |
| US7294754B2 (en) | 2004-10-19 | 2007-11-13 | Regeneron Pharmaceuticals, Inc. | Method for generating an animal homozygous for a genetic modification |
| FR2879622B1 (fr) | 2004-12-17 | 2008-02-01 | Agronomique Inst Nat Rech | Procede in vitro de production d'ovocytes ou d'oeufs presentant une modification genomique ciblee |
| US10022457B2 (en) | 2005-08-05 | 2018-07-17 | Gholam A. Peyman | Methods to regulate polarization and enhance function of cells |
| GB0615327D0 (en) | 2006-03-30 | 2006-09-13 | Univ Edinburgh | Culture medium containing kinase inhibitors and uses thereof |
| WO2007117410A2 (fr) | 2006-03-31 | 2007-10-18 | Medarex, Inc. | Animaux transgéniques exprimant des anticorps chimériques destinés à être utilisés pour la préparation d'anticorps humains |
| US7771967B2 (en) | 2006-12-22 | 2010-08-10 | The J. David Gladstone Institutes | Nucleic acid encoding apolipoprotein E-I3 |
| US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
| JP5400034B2 (ja) | 2007-04-26 | 2014-01-29 | サンガモ バイオサイエンシーズ， インコーポレイテッド | Ｐｐｐ１ｒ１２ｃ座への標的化組込み |
| SI2602323T1 (en) | 2007-06-01 | 2018-05-31 | Open Monoclonal Technology, Inc. | Compositions and procedures for inhibiting endogenous immunoglobin gene and the formation of transgenic human idiopathic antibodies |
| AU2009283194B2 (en) | 2008-08-22 | 2014-10-16 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
| US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
| EP2180058A1 (fr) | 2008-10-23 | 2010-04-28 | Cellectis | Système de recombinaison de méganucléase |
| CA2745031C (fr) | 2008-12-04 | 2018-08-14 | Sangamo Biosciences, Inc. | Edition de genome chez des rats au moyen de nucleases en doigt de zinc |
| US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
| WO2010124200A2 (fr) | 2009-04-23 | 2010-10-28 | Transposagen Biopharmaceuticals, Inc. | Modèles de rat génétiquement modifiés pour le cancer |
| US8772008B2 (en) | 2009-05-18 | 2014-07-08 | Sangamo Biosciences, Inc. | Methods and compositions for increasing nuclease activity |
| WO2011011678A2 (fr) | 2009-07-24 | 2011-01-27 | Transposagen Biopharmaceuticals, Inc. | Modèles de rats génétiquement modifiés pour les voies de signalisation cytokine-cytokine |
| US20120276537A1 (en) * | 2009-10-28 | 2012-11-01 | Kuehn Ralf | Homologous recombination in the oocyte |
| WO2011059799A1 (fr) | 2009-10-29 | 2011-05-19 | Regeneron Pharmaceuticals, Inc. | Allèles multifonctionnels |
| WO2011053957A2 (fr) | 2009-11-02 | 2011-05-05 | Gen9, Inc. | Compositions et procédés de régulation de multiples gènes d'intérêt dans une cellule |
| US9309537B2 (en) | 2009-12-01 | 2016-04-12 | National Cancer Center | Chimeric rat produced using rat embryonic stem cells in the presence of an ES cell differentiation suppressant |
| DK2816112T3 (en) | 2009-12-10 | 2018-11-19 | Univ Minnesota | TAL effector-mediated DNA modification |
| CA2951341A1 (fr) | 2009-12-21 | 2011-06-30 | Keygene N.V. | Techniques ameliorees de transfection de protoplastes |
| EA031356B1 (ru) | 2010-01-22 | 2018-12-28 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Вырезание трансгенов в генетически измененных организмах |
| EP2534163B1 (fr) * | 2010-02-09 | 2015-11-04 | Sangamo BioSciences, Inc. | Modification génomique ciblée avec des molécules donneuses partiellement monocaténaires |
| EP3156062A1 (fr) | 2010-05-17 | 2017-04-19 | Sangamo BioSciences, Inc. | Nouvelles protéines à liaison adn et leurs utilisations |
| GB201009732D0 (en) * | 2010-06-10 | 2010-07-21 | Gene Bridges Gmbh | Direct cloning |
| WO2011156723A1 (fr) | 2010-06-11 | 2011-12-15 | Regeneron Pharmaceuticals, Inc. | Production d'animaux femelles xy fertiles à partir de cellules es xy |
| EP2596011B1 (fr) * | 2010-07-21 | 2018-10-03 | Sangamo Therapeutics, Inc. | Méthodes et compositions pour modifier un locus hla |
| WO2012018726A1 (fr) | 2010-08-02 | 2012-02-09 | Cellectis Sa | Procédé d'augmentation du ciblage de gènes à cassure double-brin induite |
| WO2012129198A1 (fr) | 2011-03-23 | 2012-09-27 | Transposagen Biopharmaceuticals, Inc. | Modèles de rat génétiquement modifiés pour l'étude de l'obésité et du diabète |
| EP2718446A2 (fr) | 2011-06-07 | 2014-04-16 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Efficacité améliorée de recombinaison par inhibition d'une réparation de l'adn par nhej |
| CN107858332A (zh) | 2011-10-28 | 2018-03-30 | 瑞泽恩制药公司 | T细胞受体基因修饰小鼠 |
| WO2013141680A1 (fr) | 2012-03-20 | 2013-09-26 | Vilnius University | Clivage d'adn dirigé par arn par le complexe cas9-arncr |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| IN2014DN09261A (fr) | 2012-04-25 | 2015-07-10 | Regeneron Pharma | |
| CN104471067B (zh) | 2012-05-07 | 2020-08-14 | 桑格摩生物治疗股份有限公司 | 用于核酸酶介导的转基因靶向整合的方法和组合物 |
| MA37663B1 (fr) | 2012-05-25 | 2019-12-31 | Univ California | Procédés et compositions permettant la modification de l'adn cible dirigée par l'arn et la modulation de la transcription dirigée par l'arn |
| MX2014015204A (es) | 2012-06-12 | 2015-08-07 | Genentech Inc | Metodos y composiciones para generar alelos con inactivacion condicional. |
| CN116622704A (zh) | 2012-07-25 | 2023-08-22 | 布罗德研究所有限公司 | 可诱导的dna结合蛋白和基因组干扰工具及其应用 |
| KR102182847B1 (ko) | 2012-10-23 | 2020-11-27 | 주식회사 툴젠 | 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도 |
| EP3617309A3 (fr) | 2012-12-06 | 2020-05-06 | Sigma Aldrich Co. LLC | Modification et régulation de génome à base de crispr |
| WO2014093479A1 (fr) | 2012-12-11 | 2014-06-19 | Montana State University | Contrôle de la régulation génétique guidé par arn crispr (répétitions palindromiques groupées, courtes régulièrement espacées ) |
| DK2931898T3 (en) | 2012-12-12 | 2016-06-20 | Massachusetts Inst Technology | CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS |
| PT2771468E (pt) | 2012-12-12 | 2015-06-02 | Harvard College | Engenharia de sistemas, métodos e composições-guia otimizadas para manipulação de sequências |
| IL293526A (en) | 2012-12-12 | 2022-08-01 | Harvard College | Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications |
| WO2014093595A1 (fr) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Systèmes de composants de crispr-cas, procédés et compositions pour la manipulation de séquences |
| EP3064585B1 (fr) | 2012-12-12 | 2020-02-05 | The Broad Institute, Inc. | Fabrication et optimisation de systèmes, procédés et compositions d'enzyme améliorés pour la manipulation de séquences |
| KR20150105634A (ko) | 2012-12-12 | 2015-09-17 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작을 위한 개선된 시스템, 방법 및 효소 조성물의 유전자 조작 및 최적화 |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| WO2014093709A1 (fr) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Procédés, modèles, systèmes et appareil pour identifier des séquences cibles pour les enzymes cas ou des systèmes crispr-cas pour des séquences cibles et transmettre les résultats associés |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| EP2931899A1 (fr) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Génomique fonctionnelle employant des systèmes crispr-cas, des compositions, des procédés, des banques d'inactivation et leurs applications |
| ES2741951T3 (es) | 2012-12-17 | 2020-02-12 | Harvard College | Modificación por ingeniería genética del genoma humano guiada por ARN |
| EP2938184B1 (fr) | 2012-12-27 | 2018-10-31 | Keygene N.V. | Procédé de suppression d'une liaison génétique dans un végétal |
| WO2014127287A1 (fr) | 2013-02-14 | 2014-08-21 | Massachusetts Institute Of Technology | Procédé pour la mutagenèse ciblée in vivo |
| RU2690352C2 (ru) | 2013-02-20 | 2019-05-31 | Регенерон Фармасютикалс, Инк. | Генетическая модификация крыс |
| AU2014218621B2 (en) | 2013-02-25 | 2019-11-07 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
| JP2016507244A (ja) | 2013-02-27 | 2016-03-10 | ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）Ｈｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ ＭｕｅｎｃｈｅｎＤｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ ｕｎｄ Ｕｍｗｅｌｔ （ＧｍｂＨ） | Ｃａｓ９ヌクレアーゼによる卵母細胞における遺伝子編集 |
| WO2014143381A1 (fr) | 2013-03-09 | 2014-09-18 | Agilent Technologies, Inc. | Procédé de modification in vivo de grande séquences utilisant plusieurs sélections crispr/cas d'événements de recombinaison |
| RU2018122288A (ru) | 2013-03-14 | 2019-03-06 | Карибо Биосайенсиз, Инк. | Композиции и способы с участием нуклеиновых кислот, нацеленных на нуклеиновые кислоты |
| US20140273230A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
| US20140349400A1 (en) | 2013-03-15 | 2014-11-27 | Massachusetts Institute Of Technology | Programmable Modification of DNA |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| AU2014235968B2 (en) | 2013-03-21 | 2018-05-24 | Ospedale San Raffaele Srl | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| WO2014165825A2 (fr) | 2013-04-04 | 2014-10-09 | President And Fellows Of Harvard College | Utilisations thérapeutiques de l'édition de génome au moyen de systèmes crispr/cas |
| WO2014172470A2 (fr) | 2013-04-16 | 2014-10-23 | Whitehead Institute For Biomedical Research | Procedes de mutation, de modification ou de modulation d'acide nucleique dans une cellule ou chez un mammifere non-humain |
| SI2986729T1 (sl) | 2013-04-16 | 2019-02-28 | Regeneron Pharmaceuticals, Inc. | Ciljana sprememba genoma podgane |
| US20160040155A1 (en) | 2013-04-16 | 2016-02-11 | University Of Washington Through Its Center For Commercialization | Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering |
| EP2796558A1 (fr) | 2013-04-23 | 2014-10-29 | Rheinische Friedrich-Wilhelms-Universität Bonn | Ciblage génique amélioré et molécule porteuse d'acide nucléique, en particulier pour utilisation dans des plantes |
| US11306328B2 (en) | 2013-07-26 | 2022-04-19 | President And Fellows Of Harvard College | Genome engineering |
| MX2016007654A (es) | 2013-12-11 | 2017-08-15 | Regeneron Pharma | Metodos y composiciones para la modificacion dirigida de un genoma. |
| CN106795521B (zh) | 2014-06-06 | 2021-06-04 | 瑞泽恩制药公司 | 用于修饰所靶向基因座的方法和组合物 |
| AU2015279642B2 (en) | 2014-06-26 | 2021-03-25 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modifications and methods of use |
| CN107075483A (zh) | 2014-07-15 | 2017-08-18 | 朱诺治疗学股份有限公司 | 用于过继细胞治疗的工程改造的细胞 |
| EP3232774B1 (fr) | 2014-12-19 | 2019-10-09 | Regeneron Pharmaceuticals, Inc. | Procédés et compositions pour modification génétique ciblée par ciblage multiple en une seule étape |
-
2013
- 2013-04-25 IN IN9261DEN2014 patent/IN2014DN09261A/en unknown
- 2013-04-25 DK DK13720718.9T patent/DK2847335T3/en active
- 2013-04-25 KR KR1020147030262A patent/KR101904508B1/ko active IP Right Grant
- 2013-04-25 CN CN201811024942.8A patent/CN109536526B/zh active Active
- 2013-04-25 SG SG11201406547YA patent/SG11201406547YA/en unknown
- 2013-04-25 CA CA2869016A patent/CA2869016C/fr active Active
- 2013-04-25 MX MX2014012994A patent/MX362523B/es active IP Right Grant
- 2013-04-25 ES ES13720718.9T patent/ES2683071T3/es active Active
- 2013-04-25 JP JP2015509128A patent/JP6275120B2/ja active Active
- 2013-04-25 RU RU2014145942A patent/RU2645475C2/ru active
- 2013-04-25 BR BR112014026294-2A patent/BR112014026294B1/pt active IP Right Grant
- 2013-04-25 EP EP13720718.9A patent/EP2847335B1/fr active Active
- 2013-04-25 AU AU2013251558A patent/AU2013251558B2/en active Active
- 2013-04-25 SG SG10201702445TA patent/SG10201702445TA/en unknown
- 2013-04-25 CN CN201380030738.6A patent/CN104364380B/zh active Active
- 2013-04-25 PL PL13720718T patent/PL2847335T3/pl unknown
- 2013-04-25 US US13/870,280 patent/US9834786B2/en active Active
- 2013-04-25 PT PT137207189T patent/PT2847335T/pt unknown
- 2013-04-25 WO PCT/US2013/038165 patent/WO2013163394A1/fr active Application Filing
-
2014
- 2014-09-30 IL IL234905A patent/IL234905B/en active IP Right Grant
-
2015
- 2015-08-24 HK HK15108155.7A patent/HK1207396A1/xx unknown
-
2017
- 2017-10-24 US US15/792,112 patent/US10301646B2/en active Active
-
2018
- 2018-08-06 CY CY20181100810T patent/CY1120572T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN09261A (fr) | ||
| AU2018200955B2 (en) | Optimal maize loci | |
| MY183741A (en) | Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair | |
| AU2018201613B2 (en) | Optimal soybean loci | |
| EP3441468A3 (fr) | Procédés d'administration et compositions pour génie génomique médié par nucléase | |
| MX2017008190A (es) | Metodos y composiciones para la modificacion genetica dirigida a traves de direccionamiento multiple de una sola etapa. | |
| MX336846B (es) | Alteracion genomica dirigida. | |
| EP3313991A4 (fr) | Facteur ix modifié, et compositions, méthodes et utilisations pour un transfert de gènes dans des cellules, des organes et des tissus | |
| WO2013188522A3 (fr) | Procédés et compositions pour la génération d'allèles à inactivation conditionnelle | |
| WO2014165825A3 (fr) | Utilisations thérapeutiques de l'édition de génome au moyen de systèmes crispr/cas | |
| WO2014153470A3 (fr) | Interruption ciblée de gènes de récepteur des lymphocytes t à l'aide de nucléases protéiques à doigt de zinc génétiquement modifiées | |
| MX351043B (es) | Metodos para modificacion genomica. | |
| EP3057432A4 (fr) | Procédés d'apport et compositions pour ingénierie génomique à médiation par des nucléases dans des cellules souches hématopoïétiques | |
| WO2015073683A3 (fr) | Régulation de l'expression génique médiée par les nucléases | |
| IN2014DN08812A (fr) | ||
| WO2014033644A3 (fr) | Méthodes de génie génétique fondées sur les nucléases | |
| EP4234703A3 (fr) | Ingénierie des génomes | |
| MX369747B (es) | Modificación dirigida del genoma de rata. | |
| WO2012177810A3 (fr) | Alimentation électrique améliorée et procédés associés | |
| SG10201810110RA (en) | Extreme pcr | |
| WO2012166425A3 (fr) | Procédés d'amplification du génome total d'une cellule isolée | |
| NZ705742A (en) | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks | |
| MX2016014235A (es) | Biosintesis microbiana de ergotioneina. | |
| MX2014003889A (es) | Compuestos antivirales. | |
| WO2011156654A3 (fr) | Caractérisation de voies de cellules |